At Taj Oncology, we believe that a full range of products, from high-end oncology drugs to non-prescription drugs should be fully accessible and affordable to every patient and we consistently work on providing the best pharmaceutical solutions to the healthcare market.
This promise can be fulfilled as a result of our unique research and development facilities at our manufacturing plants in India.
We are committed to delivering only the best quality drugs backed up by the largest range of pharmaceutical products available today. We know how important it is to re-invest in the development of our products to ensure patient safety and wellbeing.
Taj Oncology embraces diversity as an essential component in the way we do business. We apply the highest standards of excellence to the purchasing and delivery of our products. We contribute positively to our community and ensure the viability of the future of our business to protect our employees and the safety of our clients.
Taj Pharma Group
A dream for new world Anchored in India and committed to its traditional values of leadership with trust, the Taj Pharma Group is spreading its footprint globally through excellence and innovation.
Each operating company in the group develops its international business as an integral element in an overall strategy, depending on the competitive dynamics of the industry in which it operates. For some businesses a focus on the export market remains the priority. For others it is developing a robust presence in domestic markets given growing population of India. And then there are Group companies, a small but growing number, that have global ambitions; additionally, synchronizing these ventures to cater Indian market remains a priority for growth.
Exports from India remain the cornerstone of the Taj Pharma Group’s international business, but different Taj companies are increasingly investing in assets overseas through Greenfield projects (such as in Spain, Germany, Middle East, Africa, Russia, and CIS Countries), joint ventures (in Sri Lanka, UK) and acquisitions.
While individual Taj companies have differing geographical imperatives, the Taj group is focusing on a clutch of priority countries, which are expected to be of strategic importance in the years ahead. The regions are UK, Sri Lanka, the Netherlands, Germany, South Africa, members of the Gulf Cooperation Council, Brazil, Vietnam, Thailand and Taiwan.
Dr. R.K.Singh, Chairman, Taj Pharmaceuticals Limited., sums up the Taj group’s efforts to internationalize its operations thus: “We hope that a several years from now we will spread our wings far beyond India, that we become a global group, operating in many countries, an Indian business conglomerate that is at home in the world, carrying the same sense of trust that we do today." We have already progressed on such efforts by our current presence in more than 40 countries.